Study S001905

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities

ClinicalTrials.gov record

Registration

Registration: NCT07553299
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: TERMINATED
Enrollment: 8
Start: 2026-06-12
Primary completion: 2026-09-11
Lead sponsor: Verdiva Bio Dev Limited
Conditions: Obesity; Overweight; Weight Maintenance
Interventions: DRUG:VRB-101; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

To identify the dose of VRB-101 for weight maintenance [Baseline to End of Treatment (Week 17)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.